Literature DB >> 26716736

Spectral electroencephalogram in liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy.

Jatinderpal Singh1, Barjesh Chander Sharma1, Sudhir Maharshi1, Vinod Puri2, Siddharth Srivastava1.   

Abstract

BACKGROUND AND AIM: Minimal hepatic encephalopathy (MHE) represents the mildest form of hepatic encephalopathy. Spectral electroencephalogram (sEEG) analysis improves the recognition of MHE by decreasing inter-operator variability and providing quantitative parameters of brain dysfunction. We compared sEEG in patients with cirrhosis with and without MHE and the effects of lactulose on sEEG in patients with MHE.
METHODS: One hundred patients with cirrhosis (50 with and 50 without MHE) were enrolled. Diagnosis of MHE was based on psychometric hepatic encephalopathy score (PHES) of ≤ -5. Critical flicker frequency, model of end-stage liver disease score, and sEEG were performed at baseline in all patients. The spectral variables considered were the mean dominant frequency (MDF) and relative power in beta, alpha, theta, and delta bands. Patients with MHE were given 3 months of lactulose, and all parameters were repeated.
RESULTS: Spectral electroencephalogram analysis showed lower MDF (7.8 ± 1.7 vs 8.7 ± 1.3 Hz, P < 0.05) and higher theta relative power (34.29 ± 4.8 vs 24 ± 6.7%, P = 001) while lower alpha relative power (28.6 ± 4.0 vs 33.5 ± 5.3%, P = .001) in patients with MHE than in patients without MHE. With theta relative power, sensitivity 96%, specificity 84%, and accuracy of 90% were obtained for diagnosis of MHE. After lactulose treatment, MHE improved in 21 patients, and significant changes were seen in MDF (7.8 ± 0.5 vs 8.5 ± 0.6), theta (34.2 ± 4.8 vs 23.3 ± 4.1%), alpha (28.6 ± 4.0 vs 35.5 ± 4.5%), and delta relative power (13.7 ± 3.5 vs 17.0 ± 3.3%) after treatment (P ≤ 0.05).
CONCLUSIONS: Spectral EEG is a useful objective and quantitative tool for diagnosis and to assess the response to treatment in patients with cirrhosis with MHE.
© 2015 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  lactulose; minimal hepatic encephalopathy; spectral EEG

Mesh:

Substances:

Year:  2016        PMID: 26716736     DOI: 10.1111/jgh.13283

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  4 in total

1.  Aberrant stability of brain functional architecture in cirrhotic patients with minimal hepatic encephalopathy.

Authors:  Li-Min Cai; Jia-Yan Shi; Qiu-Yi Dong; Jin Wei; Hua-Jun Chen
Journal:  Brain Imaging Behav       Date:  2022-06-21       Impact factor: 3.224

Review 2.  Hepatic encephalopathy: what the multidisciplinary team can do.

Authors:  Andy Liu; Eric R Yoo; Osama Siddique; Ryan B Perumpail; George Cholankeril; Aijaz Ahmed
Journal:  J Multidiscip Healthc       Date:  2017-03-24

Review 3.  Cognition-tracking-based strategies for diagnosis and treatment of minimal hepatic encephalopathy.

Authors:  Weijia Han; Huanqian Zhang; Ying Han; Zhongping Duan
Journal:  Metab Brain Dis       Date:  2020-06-03       Impact factor: 3.584

Review 4.  Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.

Authors:  Segundo Moran; Marlene López-Sánchez; María Del Pilar Milke-García; Gustavo Rodríguez-Leal
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.